Advanced tests for hereditary cancers helps ID patients’ risk
Phosphorus has released advanced tests for hereditary cancers, including prostate and kidney cancer. The tests include a high-risk panel for common cancers, a comprehensive panel spanning multiple cancer types, and fully customizable panels by specialty area covering up to 114 genes associated with inherited cancers. The high-risk panel includes 32 genes and examines the most actionable and recognized genes across cancer types to provide prophylactic and treatment options. The comprehensive panel includes 114 genes and gives broader insight into a patient’s cancer risk. Disease-specific panels include 11 total specialties including colorectal, ovarian/uterine, renal, prostate, and pediatric cancers. Validation of the inherited cancer test yielded 99.8% analytical sensitivity for single nucleotide variants (SNVs) and 99.6% for indels, Phosphorus reported. Additionally, analytical specificity is 100% for SNVs and indels alike, while positive predictive value is 99.9% for SNVs and 100% for indels.
For more information, visit www.phosphorus.com.